{"id":"W2089664277","doi":"10.3816/clc.2008.n.037","title":"An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial","year":2008,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Gemcitabine; Medicine; Oncology; Internal medicine; Cisplatin; Erlotinib Hydrochloride; Clinical endpoint; Chemotherapy; Progression-free survival; Randomized controlled trial; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009786066,0.0008764988,0.002820198,0.0002444694,0.0003355304,0.00003909002,0.0005176713,0.0003355536,0.001329199],"category_scores_gemma":[0.0006455062,0.0006416494,0.0006842968,0.0006458473,0.0004203052,0.000385058,0.0001658143,0.0006103318,0.000001289581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001112741,"about_ca_system_score_gemma":0.000996462,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001751969,"about_ca_topic_score_gemma":0.02400715,"domain_scores_codex":[0.9928305,0.0004511152,0.003855106,0.001352599,0.000866453,0.0006442476],"domain_scores_gemma":[0.9935856,0.002177595,0.001997028,0.00104358,0.0007597099,0.0004364384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8368415,0.03589637,0.106579,0.0007270726,0.004371312,0.00006033284,0.003245122,0.003861809,0.001154479,0.00001282674,0.003233864,0.004016286],"study_design_scores_gemma":[0.8818885,0.0102827,0.002204419,0.0005409341,0.002647471,0.000004777851,0.0003049595,0.09807473,0.001098973,0.000005744766,0.002408492,0.0005382663],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8898669,0.0008884983,0.000256858,0.001114139,0.001906959,0.1028988,0.002767869,0.00006297727,0.000237001],"genre_scores_gemma":[0.9187296,0.001176674,0.0005744428,0.0002072198,0.0005855125,0.07217179,0.001605762,0.0001340215,0.004814947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1043746,"threshold_uncertainty_score":0.9996035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03595857253129783,"score_gpt":0.4227494391711765,"score_spread":0.3867908666398787,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}